Harvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide new opportunities for advancing preclinical and organoid-focused therapy development. The Company?s GLP-compliant Ponemah?

preclinical data management platform now includes integrations with the new SoHo? implantable telemetry solution and the VivaMARS? high-capacity behavior monitoring system.

By integrating these new applications in a single data management platform, the Ponemah system provides users with a powerful tool for managing and analyzing data across a range of studies. The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools. Together with the Ponemah platform, the SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment.

In addition, the SoHo solution allows data to be collected over longer time periods and opens new opportunities for longitudinal studies. SoHo supports the customer?s business needs by reducing operating costs and test cycle times, enabling increased testing throughput. The VivaMARS system combines the Company?s infrared Panlab® activity monitoring technology with its Ponemah platform to create an integrated, GLP-compliant solution for real-time, high precision behavioral testing.

The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes.